Published online Nov 24, 2026. doi: 10.5306/wjco.124935
Revised: August 14, 2026
Accepted: October 22, 2026
Published online: November 24, 2026
Processing time: 142 Days and 16.9 Hours
Postoperative recurrence and metastasis significantly hinder long-term survival in colorectal cancer (CRC), with varied responses to adjuvant chemotherapy observ
To characterize the expression pattern and oncogenic function of HN1 L in CRC, investigate its association with Hippo signaling, and explore its association with postoperative risk stratification and adjuvant chemotherapy selection.
HN1 L expression and clinical relevance were assessed using transcriptomic and clinical data from The Cancer Genome Atlas, single-cell RNA sequencing data from GSE132465, immunohistochemical (IHC) analyses of 84 paraffin-embedded CRC specimens, and an independent cohort comprising 10 paired frozen CRC and adjacent normal tissues for Western blot (WB). Stable HN1 L-overexpressing and knockdown CRC cell lines underwent quantitative real-time polymerase chain reaction, WB, RNA sequencing, pathway enrichment analysis, as well as proliferation and migration assays. In vivo tumor-promoting effects of HN1 L were evaluated using xenograft models and IHC. Kaplan-Meier analysis, time-dependent receiver operating characteristic curves, Cox regression, and HN1 L expression-by-chemotherapy interaction analysis were utilized to examine clinical associations.
HN1 L exhibited upregulation in CRC, predominantly within tumor epithelial cells. Its overexpression augmented proliferation and migration, while knockdown induced the opposite effects. Endpoint xenograft outcomes and Ki-67 staining further corroborated its tumor-promoting role in vivo. Mechanistically, HN1 L diminished MOB1 and YAP phosphorylation, particularly at YAP Ser127 and Ser397, while elevating SNAIL expression, with overall YAP levels remaining largely unchanged. In the clinical cohort, baseline characteristics were generally consistent between HN1 L-high and HN1 L-low groups. High HN1 L expression correlated with reduced five-year overall survival (60% 95%CI: 34%-100% vs 96% 95%CI: 87%-100%, log-rank P = 0.039). Among HN1 L-high patients, the five-year disease-free survival (DFS) was 92% with adjuvant chemotherapy compared to 52% without. A significant HN1 L-by-chemotherapy interaction was noted for DFS (interaction hazard ratio = 0.09, 95%CI: 0.008-0.901; P = 0.031).
HN1 L promotes CRC progression by suppressing Hippo pathway activity. Elevated HN1 L expression correlates with poorer clinical outcomes and differential adjuvant chemotherapy benefit in this retrospective cohort, thereby supporting its potential role in CRC risk stratification and treatment selection.
Core Tip: This study identifies HN1 L as an oncogenic regulator in colorectal cancer (CRC). Integrated transcriptomic, cellular, xenograft, and clinical analyses demonstrate that HN1 L enhances CRC proliferation and migration by inhibiting Hippo pathway activity, primarily through reduced MOB1 and YAP phosphorylation. Clinically, high HN1 L expression was associated with poorer five-year overall survival, while an exploratory interaction analysis suggested a possible difference in adjuvant chemotherapy benefit according to HN1 L expression. These findings suggest that HN1 L may function as a chemotherapy-response indicator and a potential therapeutic target in CRC.
- Citation: Kang D, Zeng LX, Zhang RX, Ma WJ, Yang R, Wang X. HN1 L promotes colorectal cancer proliferation and migration by inhibiting the Hippo pathway. World J Clin Oncol 2026; 17(11): 124935
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/124935.htm
- DOI: https://dx.doi.org/10.5306/wjco.124935
Colorectal cancer (CRC) ranks among the most prevalent and deadly malignancies globally, representing a significant public health challenge[1,2]. The development and clinical heterogeneity of CRC are influenced by both tumor-intrinsic alterations and host-related factors. Obesity, for instance, is linked to extensive metabolic, endocrine, and immune dysregulation, including altered leptin signaling and systemic inflammatory responses[3]. Despite advancements in screening, surgical intervention, and systemic therapies, postoperative recurrence and metastasis remain significant barriers to long-term survival, particularly in advanced-stage patients[4]. While adjuvant chemotherapy can mitigate recurrence risk, treatment responses vary considerably among patients with similar characteristics, leading many to experience limited benefit or unnecessary toxicity[5-7]. Thus, reliable molecular markers are essential for enhancing postoperative risk assessment and treatment selection.
Recent research has increasingly focused on patient stratification for CRC adjuvant chemotherapy, seeking to identify subgroups with differing sensitivity or resistance to treatment[8]. Molecular profiling, biomarker analysis, and gene expression patterns have emerged as key tools for this endeavor. Clinical trials, such as GALAXY and DYNAMIC, have highlighted the significance of postoperative circulating tumor DNA in monitoring recurrence and informing adjuvant therapy decisions[9,10]. Furthermore, emerging methodologies-including biomarker profiling and artificial intelligence imaging models-provide new insights for personalized treatment selection, with the potential to optimize therapeutic efficacy and reduce unnecessary toxicity[11,12].
HN1 L, also known as JPT2, has been reported to exhibit aberrant expression in various malignancies, correlating with aggressive tumor behavior and poor prognosis. Previous studies have implicated HN1 L in multiple oncogenic signaling networks, including the MAPK, STAT3, AP-2γ, and eEF1A pathways[13-18]. However, its biological function, downstream signaling mechanisms, and clinical relevance in CRC remain poorly defined[13]. The Hippo signaling pathway serves as an evolutionarily conserved regulator of tissue homeostasis, organ growth, cell proliferation, and apoptosis[19,20]. Dysregulation of its main transcriptional effectors, YAP and TAZ, contributes to tumor initiation, progression, metastasis, and treatment resistance in various solid tumors[21,22]. Consequently, the YAP/TAZ-TEAD transcriptional complex has emerged as a promising therapeutic target. Current strategies entail inhibiting TEAD palmitoylation and directly disrupting the YAP/TAZ-TEAD interaction. The oral TEAD palmitoylation inhibitor VT3989 has demonstrated preliminary clinical activity in treating refractory solid tumors, while IAG933 has shown antitumor activity in preclinical models, including CRC and other MAPK-altered cancers when combined with pathway-targeted agents[23,24]. Nonetheless, these approaches remain at an early stage, and the upstream regulators responsible for Hippo pathway dysregulation in CRC have yet to be fully elucidated.
This study investigated the expression pattern, biological function, and signaling mechanism of HN1 L in CRC through integrated transcriptomic analyses, cellular and xenograft experiments, and evaluation of clinical cohorts. The study examined whether HN1 L promotes CRC progression by regulating Hippo pathway activity and assessed its association with postoperative outcomes and adjuvant chemotherapy benefit. Our findings highlight HN1 L as a potential upstream regulator of Hippo signaling and provide a molecular foundation for further exploring its value in CRC risk stratification and treatment selection.
Paraffin-embedded CRC specimens were obtained from 84 patients who underwent surgical resection at Sun Yat-sen University Cancer Center (SYSUCC) between 2009 and 2016. All specimens were utilized for IHC and clinical analyses, while an independent set of 10 paired frozen CRC and adjacent normal tissues was used for WB validation. No patients had received preoperative chemotherapy or radiotherapy. Clinical data, including age, sex, body mass index, pathological stage, mismatch repair (MMR) status, serum carbohydrate antigen 19-9 (CA19-9) levels, postoperative adjuvant chemotherapy, survival status, and follow-up duration, were retrieved from medical records. Pathological staging adhered to the American Joint Committee on Cancer TNM classification. The Ethics Committee of SYSUCC approved the study (No. G2022-209-01).
Gene expression profiles and corresponding clinical data for CRC patients were obtained from The Cancer Genome Atlas (TCGA) via the UCSC Xena platform. Cases with incomplete clinical information, such as missing survival status or follow-up time, were excluded from analysis. Remaining samples were included in subsequent bioinformatics evaluations. Single-cell RNA sequencing (scRNA-seq) data for CRC patients were retrieved from the GSE132465 dataset[25]. Cells were excluded if they expressed fewer than 200 or more than 6000 genes, possessed < 1000 unique molecular identifier counts, or exhibited > 20% mitochondrial gene content. To assess clustering robustness, analyses were repeated using a stricter mitochondrial transcript threshold of 10% in epithelial cells. Although fewer cells were retained (18539 and 11514 epithelial cells), the major cell populations and overall clustering patterns remained largely unchanged (Supplementary Figure 1A). Data preprocessing, normalization, and downstream analyses were performed in R (version 4.5.1) using the Seurat package (v5.0.1).
Total RNA was extracted from CRC cell lines using TRIzol reagent (ThermoFisher) according to the manufacturer’s instructions. RNA sequencing was performed using 3 independent biological replicates per group. Each biological replicate was independently cultured and processed. RNA libraries were subsequently prepared and sequenced on the Illumina NovaSeq platform. Raw sequencing reads were processed to remove adapter sequences and low-quality bases, and then aligned to the human reference genome (GRCh38). Differentially expressed genes (DEGs) were identified using the DESeq2 package (v1.49.2) with an adjusted P value < 0.05 and an absolute log2 fold change > 1. Pathway enrichment analysis and single-sample gene set enrichment analysis (ssGSEA) were performed using the clusterProfiler (v4.17.0) and GSVA (v2.3.1) packages, respectively. Survival analyses were conducted using the survival package (v3.8.3) and the Kaplan-Meier plotter database. Predictive performance was assessed using time-dependent receiver operating characteristic curves implemented in the timeROC package (v0.4). Additional visualizations were generated using functions from the ggplot2 package (v3.5.2).
Human CRC cell lines DLD1, LOVO, RKO, HT29, HCT116, SW480, SW620, and THC8307, along with the normal human colon cell line CCD841, were obtained from the American Type Culture Collection. Cells were cultured in DMEM or RPMI-1640 (GIBCO) supplemented with 10% fetal bovine serum (FBS, Bio-Channel) and 1% penicillin-streptomycin (GIBCO) in a humidified atmosphere containing 5% CO2 at 37 °C. HN1 L expression was initially assessed in the eight CRC cell lines. HCT116 and LOVO cells, which exhibited relatively low basal HN1 L expression, were selected for HN1 L overexpression experiments, while HT29 and RKO cells, which had relatively high basal HN1 L expression, were chosen for HN1 L knockdown experiments. CCD841 cells served as a normal epithelial expression control but were excluded from functional assays. All cell lines underwent authentication through short tandem repeat profiling and were screened monthly for mycoplasma contamination.
The HN1 L overexpression plasmid, two short hairpin RNA (shRNA) plasmids targeting human HN1 L, and their corresponding negative-control plasmids were purchased from RiboBio (China). The shRNA target sequences were as follows: Sh-HN1 L#1: 5′-GGCGTAAGCAGAAACACTAAC-3′; sh-HN1 L#2: 5′-CGCCTGTATTTGGAAGATTTAA-3′. Both shRNAs were initially evaluated for knockdown efficiency. Based on this initial screening, sh-HN1 L#2, which showed greater knockdown efficiency, was selected for the subsequent functional experiments.
Lentiviral particles were produced in HEK293T cells using Lipofectamine 3000 (ThermoFisher, #L3000) per the manufacturer’s instructions. CRC cells were infected with lentiviruses carrying the HN1 L overexpression construct, sh-HN1 L constructs, or the corresponding controls. Stable cell lines were selected using puromycin (Solarbio, #P8230) for 2 weeks. HN1 L overexpression and knockdown efficiency were validated by Western blot (WB) and real-time quantitative PCR analysis (qRT-PCR).
Total RNA was extracted using TRIzol reagent (ThermoFisher) according to the manufacturer’s recommendations. Complementary DNA was synthesized using the Color Reverse Transcription Kit (EZBioscience, #A0010CGQ). Quantitative real-time PCR was performed using Color SYBR Green qPCR Master Mix (EZBioscience, #A0012) on a LightCycler 480 System (Roche). Relative gene expression was normalized to the internal reference gene and calculated using the 2-ΔΔCT method. The sequences of primers were as follows: GAPDH forward: 5′-GGAGCGAGATCCCTCCAA
Cells were lysed in RIPA buffer supplemented with protease and phosphatase inhibitors for 30 minutes. Following centrifugation, the protein-containing supernatant was mixed with loading buffer and denatured by boiling at 100 °C for 10 minutes. Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5% non-fat milk and incubated overnight at 4 °C with primary antibodies against HN1 L (Proteintech, #16285, 1:1000), YAP/TAZ (CST, #8418S, 1:1000), phosphorylated YAP (Ser127, CST, #13008T; Ser397, CST, #13619S; 1:1000), phosphorylated MOB1 (Biodragon, #BD-PP1406, 1:1000), LATS1 (CST, #3477T, 1:1000), SNAIL (CST, #3879S, 1:1000), and GAPDH (CST, #2118S, 1:4000). After incubation with HRP-conjugated secondary antibodies, protein bands were detected using enhanced chemiluminescence and quantified with ImageJ software.
Paraffin-embedded tissue sections from CRC patients and mouse models were deparaffinized, rehydrated, and subjected to antigen retrieval. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide. Sections were incubated overnight at 4 °C with primary antibodies against HN1 L (Proteintech, #16285, 1:200), Ki-67 (CST, #9449T, 1:1000), and phosphorylated YAP (CST, #13008T, 1:500), followed by incubation with HRP-conjugated secondary antibodies at room temperature for 80 minutes. Staining was developed using DAB substrate and counterstained with hematoxylin. IHC staining was quantified using HALO software. Tumor regions were manually annotated, while stromal areas, tissue folds, and other staining artifacts were excluded. Cells were classified as negative, weakly positive, moderately positive, or strongly positive based on DAB staining intensity. The same intensity thresholds and analysis settings were applied to all tissue sections. An H-score was calculated using the following formula: H-score = 1 × percentage of weakly stained cells + 2 × percentage of moderately stained cells + 3 × percentage of strongly stained cells. Patients were divided into HN1 L-high and HN1 L-low groups using the median H-score of the 84-patient cohort as the cutoff.
Cell proliferation was evaluated using the Cell Counting Kit-8 (CCK-8) assay (DOJINDO) and a colony formation assay. For the CCK-8 assay, 1000 cells were seeded into 96-well plates, and absorbance at 450 nm was measured daily. For the colony formation assay, cells were plated in 6-well plates and cultured for 10-14 days before being fixed with methanol and stained with crystal violet (Solarbio). Colonies consisting of more than 50 cells were counted.
Real-time cell proliferation was monitored using the IncuCyte live-cell imaging system. Briefly, 1000 cells were seeded into each well of a 96-well plate and cultured under standard conditions. Phase-contrast images were automatically captured at regular intervals, and cell growth was analyzed using the IncuCyte software. The cell index was calculated as the area occupied by cells relative to the total image area and is therefore a dimensionless value ranging from 0 to 1. A higher cell index indicates a larger cell-covered area and increased cell proliferation.
Cell migration ability was assessed using Transwell chambers (Corning) with 8 μm pore membranes. Cells suspended in serum-free medium were seeded into the upper chamber, while medium containing 10% FBS was added to the lower chamber as a chemoattractant. After incubation, migrated cells were fixed with methanol and stained with crystal violet. Images from three random fields were captured and analyzed using ImageJ software.
HN1 L-modified CRC cells were treated with the Hippo pathway activator α-Ionone (MCE, #HY-N8847, 200 μM for 48 hours) or the LATS kinase inhibitor TRULI (MCE, #HY-138489, 10 μM for 48 hours). HCT116, LOVO, and HT29 cells with HN1 L overexpression or knockdown were separately treated with α-Ionone or TRULI. Corresponding control cells received an equivalent volume of DMSO. The effects of pharmacological Hippo pathway modulation were subsequently evaluated by colony formation, CCK-8, Transwell migration, and WB assays. Pharmacological modulation of Hippo signaling was further assessed by WB of p-MOB1, LATS1, YAP/TAZ, and p-YAP.
All animal experiments were approved by the Animal Ethics Committee of SYSUCC (No. L102042020120B). Six-week-old female BALB/c nude mice (Gempharmatech-GD) were used for subcutaneous xenograft experiments. Mice were randomly allocated to the indicated control and HN1 L-modified groups, with at least 5 mice per group. Each mouse was considered one independent biological unit. A total of 1 × 106 CRC cells stably overexpressing or silencing HN1 L, or the corresponding control cells, were injected subcutaneously into each mouse. Animals were monitored throughout the experiment according to the approved institutional animal-care protocol. Tumor tissues were then fixed, paraffin-embedded, and processed for immunohistochemical analysis.
Quantitative data are presented as mean ± SD. Unless otherwise specified, in vitro experiments were independently repeated at least three times using separately prepared cell samples. Statistical analyses were performed using GraphPad Prism 9.0 and R software (4.5.1). Comparisons between two groups were conducted using Student’s t-test, while multiple group comparisons were analyzed by one-way analysis of variance. Survival curves were generated using the Kaplan-Meier method and compared using the log-rank test. Univariable Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95%CIs for overall survival (OS). Because only six deaths occurred in the clinical cohort, multivariable Cox regression for OS was not performed to avoid model overfitting. For disease-free survival, an exploratory Cox model including the main effects of HN1 L expression and adjuvant chemotherapy and their interaction term (HN1 L × chemotherapy) was fitted. The interaction analysis of a separate Cox model was evaluated using the Wald test and likelihood ratio test. Time-dependent receiver operating characteristic curves were used to evaluate predictive performance. All statistical tests were two-sided, and P < 0.05 was considered statistically significant.
Although HN1 L has been implicated in the progression of several solid tumors, its expression pattern and cellular distribution in CRC remain unclear. Analysis of the TCGA-CRC dataset revealed that HN1 L expression was significantly elevated in tumor tissues compared to normal tissues, with further increases observed in metastatic tumors (Figure 1A). Differential expression analysis also indicated co-expression of HN1 L with multiple cancer-associated genes (Figure 1B). Survival analysis showed that patients with high HN1 L expression experienced shorter OS than those with low HN1 L expression (Figure 1C).
HN1 L expression was further examined in CRC cell lines and clinical specimens. WB demonstrated variable HN1 L expression across CRC cell lines, with relatively low levels in HCT116 and LOVO cells and higher expression in HT29 and RKO cells compared to the normal colonic epithelial cell line CCD841 (Figure 1D). Additionally, HN1 L protein expression was higher in CRC tissues than in paired adjacent normal tissues in an independent set of 10 frozen specimens (Figure 1E). Immunohistochemistry analysis consistently showed stronger HN1 L staining in advanced-stage tumors (Figure 1F).
scRNA-seq analysis of GSE132465 further indicated that HN1 L was predominantly expressed in epithelial cells rather than immune cells (Figure 1G-I). Approximately 40% of epithelial cells expressed HN1 L, with a mean normalized expression level of 0.20, while only 1.7% of T cells expressed HN1 L, with a mean expression level of 0.02. HN1 L expression was also higher in tumors than in normal epithelial cells. Sensitivity analysis using a stricter mitochondrial transcript threshold (< 10%) reduced the number of retained epithelial cells from 18539 to 11514 but did not materially alter the overall clustering structure (Supplementary Figure 1A).
These findings demonstrate that HN1 L is upregulated in CRC, particularly in the tumor epithelial compartment, and that its elevated expression is associated with advanced disease and poorer survival outcomes.
Based on the basal expression patterns of HN1 L across CRC cell lines, HCT116 and LOVO cells were selected for HN1 L overexpression, whereas HT29 and RKO cells were selected for HN1 L knockdown. Following the initial screening of two HN1 L-targeting shRNAs, sh-HN1 L#2 was used for subsequent functional experiments. The efficiency of HN1 L overexpression and silencing was confirmed at both the protein and mRNA levels by WB and qRT-PCR, respectively (Figure 2A and Supplementary Figure 1B).
Colony formation and real-time proliferation assays showed that HN1 L overexpression significantly enhanced CRC cell growth, whereas HN1 L knockdown led to the opposite effects (Figure 2B and C). Consistently, Transwell assays demonstrated that HN1 L overexpression increased cell migration, while HN1 L depletion reduced migratory capacity (Figure 2D). These findings indicate that HN1 L promotes proliferative and migratory phenotypes in CRC cells.
The tumor-promoting effect of HN1 L was further examined using subcutaneous xenograft models. Representative endpoint xenograft images were visually consistent with greater tumor formation following HN1 L overexpression and reduced tumor formation following HN1 L knockdown (Figure 2E). IHC analysis further showed increased Ki-67 staining in HN1 L-overexpressing tumors and reduced Ki-67 staining in HN1 L-knockdown tumors (Figure 2F).
These findings support a tumor-promoting role of HN1 L in CRC, enhancing its tumorigenic potential both in vitro and in vivo.
To investigate the signaling pathways associated with HN1 L in CRC, patients in the TCGA-CRC cohort were stratified into HN1 L-high and HN1 L-low groups. DEGs between the two groups were enriched in several cancer-related pathways, including the MAPK, WNT, and Hippo pathways (Figure 3A). ssGSEA further indicated a negative association between HN1 L expression and Hippo pathway activity, alongside a positive association with WNT pathway activity (Figure 3B). Consistently, WNT-related genes were predominantly upregulated, while Hippo-related genes were downregulated in the HN1 L-high group (Figure 3C). In the scRNA-seq dataset GSE132465, key Hippo components TAZ and MOB1 showed distinct expression patterns relative to HN1 L (Figure 3D).
RNA sequencing of HN1 L-overexpressing CRC cells and corresponding controls identified significant enrichment of Hippo signaling (Figure 3E), and protein-protein interaction network analysis supported the involvement of this pathway (Figure 3F). WB showed that HN1 L overexpression reduced MOB1 phosphorylation and YAP phosphorylation at Ser127 and Ser397, while increasing SNAIL expression. Conversely, HN1 L knockdown resulted in increased MOB1 and YAP phosphorylation and reduced SNAIL expression (Figure 3G). Notably, total YAP protein abundance remained largely unchanged, suggesting that HN1 L primarily modulates YAP phosphorylation rather than total YAP expression. Additional WB analysis in HCT116 and RKO cells showed results consistent with those observed in LOVO and HT29 cells (Supplementary Figure 1C). Consistent with these findings, xenograft IHC analysis revealed lower p-YAP staining in HN1 L-overexpressing tumors and higher p-YAP staining following HN1 L knockdown (Figure 3H).
These findings indicate that HN1 L inhibits the phosphorylation of key proteins in the Hippo signaling pathway, thereby contributing to tumorigenesis in CRC.
To further assess the inhibitory effect of HN1 L on Hippo signaling, HN1 L-modified cell lines were treated with the pathway-specific inhibitor TRULI and the agonist α-Ionone[26,27] (Figure 4A-E). As anticipated, TRULI enhanced cell proliferation and migration, whereas α-Ionone suppressed these aggressive tumor phenotypes. Notably, in HN1 L-overexpressing HCT116 and LOVO cells, HN1 L partially reversed the tumor-suppressive effects of α-Ionone. Conversely, in HT29 cells with HN1 L knockdown, the pro-tumorigenic effects of TRULI were diminished.
To further assess pathway modulation, WB was performed to examine p-MOB1, LATS1, YAP/TAZ, and p-YAP under the indicated pharmacological treatment conditions. The observed changes in Hippo pathway-associated proteins following α-Ionone or TRULI treatment were consistent with pharmacological modulation of Hippo signaling (Figure 4F).
These findings suggest that HN1 L promotes tumorigenesis by modulating the Hippo signaling pathway, highlighting HN1 L as a potential therapeutic target for the Hippo pathway in CRC.
The clinical relevance of HN1 L expression was then evaluated. Analysis of the TCGA-CRC cohort indicated higher HN1 L expression in patients with stage II/III disease, which was associated with progressive disease and poorer OS (Figure 5A-C).
HN1 L expression was subsequently assessed by IHC in the SYSUCC cohort of 84 patients, including 53 who received postoperative adjuvant chemotherapy and 31 who did not. Patients were categorized into HN1 L-high and HN1 L-low groups using the median H-score as the cutoff (Figure 5D). No significant differences were observed in clinical characteristics across the two groups, including age, sex, BMI, MMR status, TNM stage, tumor markers, and chemotherapy status (all P > 0.05; Table 1). The median OS follow-up times were 63.8 and 51.1 months in the HN1 L-low and HN1 L-high groups, respectively, while the corresponding DFS follow-up times were 56.2 and 48.4 months. Patients with high HN1 L expression exhibited lower five-year OS compared to those with low expression [60% (95%CI: 34%-100%) vs 96% (95%CI: 87%-100%), log-rank P = 0.039; Figure 5E]. No significant difference in DFS was noted between the two expression groups, although time-dependent ROC analysis indicated potential discriminatory value, particularly at one year (Figure 5F and G). Given the limited number of OS events (six deaths), only univariable Cox regression was performed. High HN1 L expression was associated with an increased estimated risk of death (HR = 7.22, 95%CI: 0.82-63.2; P = 0.07), although the association did not reach statistical significance (Table 2).
| HN1 L-low (n = 42) | HN1 L-high (n = 42) | P value | |
| Age | |||
| 54.4 ± 9.22 | 52.0 ± 13.0 | 0.34 | |
| 55.0 (34.0-75.0) | 51.5 (25.0-77.0) | ||
| Sex | |||
| Female | 15 (35.7) | 19 (45.2) | 0.505 |
| Male | 27 (64.3) | 23 (54.8) | |
| BMI | |||
| 22.5 ± 3.58 | 22.1 ± 2.99 | 0.524 | |
| 22.2 (15.4-30.9) | 21.7 (16.8-28.9) | ||
| MMR status | |||
| dMMR | 5 (11.9) | 3 (7.1) | 0.909 |
| pMMR | 26 (61.9) | 23 (54.8) | |
| Missing | 11 (26.2) | 16 (38.1) | |
| OS outcome | |||
| Alive | 40 (95.2) | 38 (90.5) | 0.672 |
| Dead | 2 (4.8) | 4 (9.5) | |
| OS follow-up time | |||
| 62.4 ± 18.1 | 54.6 ± 26.1 | 0.116 | |
| 63.8 (32.6-98.4) | 51.1 (12.6-100) | ||
| DFS outcome | |||
| Disease-free | 34 (81.0) | 36 (85.7) | 0.77 |
| Recurrence or death | 8 (19.0) | 6 (14.3) | |
| DFS follow-up time | |||
| 57.1 ± 21.4 | 52.0 ± 26.7 | 0.34 | |
| 56.2 (13.7-98.4) | 48.4 (5.10-100) | ||
| TNM stage | |||
| I | 4 (9.5) | 3 (7.1) | 0.923 |
| II | 30 (71.4) | 31 (73.8) | |
| III | 8 (19.0) | 8 (19.0) | |
| CEA | |||
| 22.0 ± 109 | 7.27 ± 10.6 | 0.388 | |
| 2.98 (0.231-708) | 2.85 (0.460-55.4) | ||
| CA19-9 | |||
| 57.6 ± 125 | 82.4 ± 284 | 0.607 | |
| 15.6 (0.600-592) | 16.0 (0.600-1820) | ||
| Chemotherapy | |||
| No | 17 (40.5) | 14 (33.3) | 0.651 |
| Yes | 25 (59.5) | 28 (66.7) |
| Variables | HR (95%CI) | P value |
| Age | 1.03 (0.94-1.13) | 0.45 |
| Sex | 3.06 (0.34-27.44) | 0.31 |
| BMI | 0.82 (0.61-1.10) | 0.19 |
| CEA | 0.99 (0.98-1.01) | 0.87 |
| CA19-9 | 0.99 (0.99-1.00) | 0.96 |
| HN1 L group | 7.22 (0.82-63.2) | 0.07 |
Among patients with high HN1 L expression, the five-year DFS was 92% in those who received adjuvant chemotherapy compared to 52% in those who did not, while this association was less pronounced in the HN1 L-low group (Figure 5H and I). An exploratory Cox model including HN1 L expression, adjuvant chemotherapy, and their interaction term demonstrated an HN1 L expression-by-chemotherapy interaction for DFS (interaction HR = 0.09, 95%CI: 0.008-0.901; Wald P = 0.041; likelihood ratio test P = 0.031), indicating that the association between adjuvant chemotherapy and DFS varied according to HN1 L expression. Additionally, lower serum CA19-9 levels were observed in patients receiving adjuvant chemotherapy than in those not receiving it (Figure 5J).
These exploratory results suggest that the association between adjuvant chemotherapy and DFS may differ according to HN1 L expression and require validation in an independent cohort.
This study characterizes the biological function, signaling mechanism, and clinical relevance of HN1 L in CRC. Integrated analyses of public transcriptomic datasets, clinical specimens, CRC cell models, and xenograft tissues showed that HN1 L is upregulated in CRC and predominantly expressed in the tumor epithelial compartment. Functional experiments demonstrated that HN1 L promotes CRC cell proliferation and migration. Mechanistically, HN1 L was associated with reduced MOB1 and YAP phosphorylation and suppression of Hippo pathway activity. Clinical analyses further suggested a link between HN1 L expression and postoperative outcomes as well as differential benefits from adjuvant chemotherapy.
HN1 L has previously been associated with aggressive behavior and poor prognosis in several malignancies[13-18]. Consistent with these findings, HN1 L expression was elevated in primary CRC tissues and further increased in metastatic lesions. Single-cell analysis confirmed that HN1 L was primarily expressed in epithelial cells rather than T cells, supporting a predominantly tumor-related source of its increased expression in CRC. HN1 L overexpression enhanced proliferative and migratory phenotypes, while its knockdown resulted in the opposite effects. Endpoint xenograft findings and corresponding Ki-67 staining also supported its tumor-promoting role in vivo. These results extend the oncogenic relevance of HN1 L to CRC, suggesting that it contributes to tumor progression through tumor-intrinsic mechanisms.
The Hippo pathway is a conserved regulator of tissue homeostasis, cell proliferation, and tumor progression[19-22]. Transcriptomic and experimental analyses indicated that HN1 L promotes CRC progression by suppressing Hippo pathway activity. HN1 L overexpression led to reduced MOB1 phosphorylation and YAP phosphorylation at Ser127 and Ser397 while increasing SNAIL expression; conversely, HN1 L knockdown induced the opposite changes. Importantly, total YAP protein abundance remained largely unchanged, suggesting that HN1 L primarily regulates YAP at the post-translational level rather than through overall expression modulation. Since YAP phosphorylation influences its subcellular localization and transcriptional activity, reduced phosphorylation could favor YAP activation, although nuclear translocation was not directly examined in this study. Pharmacological rescue experiments with α-Ionone and TRULI further supported the functional dependence of HN1 L-mediated proliferative and migratory effects on Hippo pathway activity. The precise molecular events linking HN1 L to the Hippo kinase cascade remain unclear. HN1 L/JPT2 has been identified as an NAADP-binding protein involved in intracellular Ca²⁺ signaling[13], raising the possibility that it modulates upstream Hippo pathway components through Ca²⁺ dependent mechanisms. Additionally, previously reported associations of HN1 L with the AP-2γ/METTL13 and METTL13/eEF1A signaling axes suggest potential influences on Hippo activity through broader transcriptional or post-translational regulatory networks[14,18]. However, direct interactions between HN1 L and MOB1, YAP, or other Hippo pathway components were not examined. Further studies using protein-interaction analyses and targeted mechanistic experiments are thus required to delineate the intermediate regulators linking HN1 L to MOB1-YAP phosphorylation.
Adjuvant chemotherapy reduces postoperative recurrence risk in CRC, but clinical benefit varies substantially among patients[28]. In our cohort, the measured clinical characteristics were generally comparable between the HN1 L-high and HN1 L-low groups. High HN1 L expression was associated with lower five-year OS in Kaplan-Meier analysis. However, the association did not reach statistical significance in univariable Cox analysis, and the wide confidence interval reflected the limited number of survival events. Because only six deaths occurred, multivariable Cox analysis was not performed to avoid model overfitting. Therefore, the current findings suggest an adverse prognostic trend but do not establish HN1 L as an independent prognostic factor. Among patients with high HN1 L expression, five-year DFS was 92% in those receiving adjuvant chemotherapy compared with 52% in those not receiving chemotherapy, whereas the association was less evident in the HN1 L-low group. Importantly, the formal interaction analysis demonstrated a significant interaction between HN1 L expression and adjuvant chemotherapy for DFS, indicating that the association between chemotherapy and clinical outcome differed according to HN1 L expression. These results support the potential value of HN1 L for identifying patients with differential chemotherapy benefit, although they should not be interpreted as sufficient evidence for direct treatment selection. In addition, lower serum CA19-9 levels were observed in patients who received chemotherapy than in those who did not. Because this was a between-group comparison rather than an analysis of paired measurements before and after treatment, it does not demonstrate that chemotherapy directly reduced CA19-9 levels.
Several limitations should be acknowledged. The clinical analysis was conducted in a relatively small, retrospective, single-center cohort with a limited number of survival events, which may restrict statistical power. Some historical data, including MMR status and detailed chemotherapy regimens, were incomplete, potentially introducing residual confounding. Furthermore, the clinical findings were not validated in an independent cohort. Additionally, the precise mechanisms linking HN1 L to the Hippo kinase cascade remain unresolved, and direct interactions between HN1 L and key pathway components such as MOB1 or YAP were not examined. Therefore, larger multicenter prospective studies and more detailed mechanistic investigations are needed to validate the clinical relevance of HN1 L and clarify its regulation of Hippo signaling.
Collectively, these findings identify HN1 L as a tumor-promoting regulator associated with the suppression of Hippo pathway activity in CRC. HN1 L may also hold potential value in postoperative risk stratification and in identifying pati
HN1 L promotes CRC progression by inhibiting Hippo pathway activity, with high HN1 L expression associated with poorer clinical outcomes and an exploratory analysis suggesting a possible interaction with adjuvant chemotherapy for DFS, supporting further investigation of its potential clinical relevance in CRC.
| 1. | Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467-1480. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4063] [Cited by in RCA: 3734] [Article Influence: 533.4] [Reference Citation Analysis (40)] |
| 2. | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 76817] [Cited by in RCA: 71803] [Article Influence: 14360.6] [Reference Citation Analysis (115)] |
| 3. | Alshammary RAA, Alshammary AG, Hameed WM, Al-Karawi AS. Multisystem effects of obesity: dysregulation of leptin, thyroid hormones, autoantibodies, immune and neurological responses. Egypt J Immunol. 2025;32:101-109. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 4. | Burnett-Hartman AN, Lee JK, Demb J, Gupta S. An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer. Gastroenterology. 2021;160:1041-1049. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 236] [Cited by in RCA: 223] [Article Influence: 44.6] [Reference Citation Analysis (10)] |
| 5. | Puccini A, Lenz HJ. Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting. Nat Rev Clin Oncol. 2018;15:77-78. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 24] [Cited by in RCA: 33] [Article Influence: 3.7] [Reference Citation Analysis (3)] |
| 6. | Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465-1471. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 630] [Cited by in RCA: 588] [Article Influence: 39.2] [Reference Citation Analysis (14)] |
| 7. | Gomez D, Calderón C, Carmona-Bayonas A, Cacho Lavin D, Muñoz MM, Martinez Cabañez R, Jimenez-Fonseca P. Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. Clin Transl Oncol. 2021;23:657-662. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 18] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
| 8. | Yang L, Yang J, Kleppe A, Danielsen HE, Kerr DJ. Personalizing adjuvant therapy for patients with colorectal cancer. Nat Rev Clin Oncol. 2024;21:67-79. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 95] [Cited by in RCA: 94] [Article Influence: 47.0] [Reference Citation Analysis (1)] |
| 9. | Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, Yoshino T, Oki E. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30:3272-3283. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 25] [Cited by in RCA: 207] [Article Influence: 103.5] [Reference Citation Analysis (3)] |
| 10. | Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan SA, Horvath L, Karapetis C, Shannon J, Singh M, Yip D, Ananda S, Underhill C, Ptak J, Silliman N, Dobbyn L, Popoli M, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31:1509-1518. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 148] [Cited by in RCA: 111] [Article Influence: 111.0] [Reference Citation Analysis (0)] |
| 11. | Kleppe A, Skrede OJ, De Raedt S, Hveem TS, Askautrud HA, Jacobsen JE, Church DN, Nesbakken A, Shepherd NA, Novelli M, Kerr R, Liestøl K, Kerr DJ, Danielsen HE. A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study. Lancet Oncol. 2022;23:1221-1232. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 85] [Cited by in RCA: 68] [Article Influence: 17.0] [Reference Citation Analysis (4)] |
| 12. | Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54:5-16. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 314] [Cited by in RCA: 299] [Article Influence: 27.2] [Reference Citation Analysis (3)] |
| 13. | Roggenkamp HG, Khansahib I, Hernandez C LC, Zhang Y, Lodygin D, Krüger A, Gu F, Möckl F, Löhndorf A, Wolters V, Woike D, Rosche A, Bauche A, Schetelig D, Werner R, Schlüter H, Failla AV, Meier C, Fliegert R, Walseth TF, Flügel A, Diercks BP, Guse AH. HN1L/JPT2: A signaling protein that connects NAADP generation to Ca(2+) microdomain formation. Sci Signal. 2021;14:eabd5647. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 39] [Cited by in RCA: 84] [Article Influence: 16.8] [Reference Citation Analysis (0)] |
| 14. | Li L, Zheng YL, Jiang C, Fang S, Zeng TT, Zhu YH, Li Y, Xie D, Guan XY. HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma. Cell Death Differ. 2019;26:2268-2283. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 30] [Cited by in RCA: 61] [Article Influence: 8.7] [Reference Citation Analysis (0)] |
| 15. | Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. 2018;10:212-227. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 32] [Cited by in RCA: 45] [Article Influence: 5.0] [Reference Citation Analysis (0)] |
| 16. | Li L, Zeng TT, Zhang BZ, Li Y, Zhu YH, Guan XY. Overexpression of HN1L promotes cell malignant proliferation in non-small cell lung cancer. Cancer Biol Ther. 2017;18:904-915. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 17] [Cited by in RCA: 25] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
| 17. | Jiao D, Zhang J, Chen P, Guo X, Qiao J, Zhu J, Wang L, Lu Z, Liu Z. HN1L promotes migration and invasion of breast cancer by up-regulating the expression of HMGB1. J Cell Mol Med. 2021;25:397-410. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 16] [Cited by in RCA: 27] [Article Influence: 5.4] [Reference Citation Analysis (0)] |
| 18. | Wu Q, Hu Q, Hai Y, Li Y, Gao Y. METTL13 facilitates cell growth and metastasis in gastric cancer via an eEF1A/HN1L positive feedback circuit. J Cell Commun Signal. 2023;17:121-135. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 22] [Reference Citation Analysis (0)] |
| 19. | Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7:376. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 574] [Cited by in RCA: 583] [Article Influence: 145.8] [Reference Citation Analysis (3)] |
| 20. | Ma S, Meng Z, Chen R, Guan KL. The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem. 2019;88:577-604. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1181] [Cited by in RCA: 1067] [Article Influence: 152.4] [Reference Citation Analysis (18)] |
| 21. | Calses PC, Crawford JJ, Lill JR, Dey A. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. Trends Cancer. 2019;5:297-307. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 135] [Cited by in RCA: 318] [Article Influence: 45.4] [Reference Citation Analysis (0)] |
| 22. | Mohajan S, Jaiswal PK, Vatanmakarian M, Yousefi H, Sankaralingam S, Alahari SK, Koul S, Koul HK. Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett. 2021;507:112-123. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 23] [Cited by in RCA: 90] [Article Influence: 18.0] [Reference Citation Analysis (1)] |
| 23. | Yap TA, Kwiatkowski DJ, Dagogo-Jack I, Offin M, Zauderer MG, Kratzke R, Desai J, Body A, Millward M, Tolcher AW, Raghav KPS, Thurston A, Post L, Dorr FA, Tang TT, Li Y, Sharma N, Kindler HL. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025;31:4281-4290. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 7] [Cited by in RCA: 58] [Article Influence: 58.0] [Reference Citation Analysis (0)] |
| 24. | Chapeau EA, Sansregret L, Galli GG, Chène P, Wartmann M, Mourikis TP, Jaaks P, Baltschukat S, Barbosa IAM, Bauer D, Brachmann SM, Delaunay C, Estadieu C, Faris JE, Furet P, Harlfinger S, Hueber A, Jiménez Núñez E, Kodack DP, Mandon E, Martin T, Mesrouze Y, Romanet V, Scheufler C, Sellner H, Stamm C, Sterker D, Tordella L, Hofmann F, Soldermann N, Schmelzle T. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer. 2024;5:1102-1120. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 33] [Cited by in RCA: 130] [Article Influence: 65.0] [Reference Citation Analysis (2)] |
| 25. | Lee HO, Hong Y, Etlioglu HE, Cho YB, Pomella V, Van den Bosch B, Vanhecke J, Verbandt S, Hong H, Min JW, Kim N, Eum HH, Qian J, Boeckx B, Lambrechts D, Tsantoulis P, De Hertogh G, Chung W, Lee T, An M, Shin HT, Joung JG, Jung MH, Ko G, Wirapati P, Kim SH, Kim HC, Yun SH, Tan IBH, Ranjan B, Lee WY, Kim TY, Choi JK, Kim YJ, Prabhakar S, Tejpar S, Park WY. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nat Genet. 2020;52:594-603. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 702] [Cited by in RCA: 635] [Article Influence: 105.8] [Reference Citation Analysis (4)] |
| 26. | Kastan N, Gnedeva K, Alisch T, Petelski AA, Huggins DJ, Chiaravalli J, Aharanov A, Shakked A, Tzahor E, Nagiel A, Segil N, Hudspeth AJ. Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues. Nat Commun. 2021;12:3100. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 70] [Cited by in RCA: 163] [Article Influence: 32.6] [Reference Citation Analysis (0)] |
| 27. | Yoon YE, Jung YJ, Lee SJ. A Food Odorant, α-Ionone, Inhibits Skin Cancer Tumorigenesis by Activation of OR10A6. Mol Nutr Food Res. 2024;68:e2400085. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 5] [Reference Citation Analysis (0)] |
| 28. | Kosmider S, Lipton L. Adjuvant therapies for colorectal cancer. World J Gastroenterol. 2007;13:3799-3805. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 21] [Cited by in RCA: 27] [Article Influence: 1.4] [Reference Citation Analysis (0)] |